(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.59%.
Celldex Therapeutics's earnings in 2026 is -$309,062,000.On average, 15 Wall Street analysts forecast CLDX's earnings for 2026 to be -$333,588,686, with the lowest CLDX earnings forecast at -$347,923,158, and the highest CLDX earnings forecast at -$305,972,246. On average, 15 Wall Street analysts forecast CLDX's earnings for 2027 to be -$332,355,529, with the lowest CLDX earnings forecast at -$384,792,205, and the highest CLDX earnings forecast at -$262,261,925.
In 2028, CLDX is forecast to generate -$266,424,813 in earnings, with the lowest earnings forecast at -$397,186,614 and the highest earnings forecast at -$106,389,272.